Introduction/Background

In our study, the factors determining persistence and clearance by cytology and HPV testing in cervical cancer screening were questioned. We tried to determine the relationship between persistence and variables such as gravidity, parity, early sexual intercourse, multiple sexual partners, history of oral contraceptive use, history of condom use, history of smoking and alcohol use. Thus, by determining the factors affecting the persistence of HPV, it was tried to determine the patient groups that should be carefully screened and treated.

Methodology

The study included female patients who applied to our clinic and were screened by cytology and HPV test. Cytology and HPV screening were performed again in these patients. The patients were examined in two groups as persistent and non-persistent. Age, age at first intercourse, age at marriage, gravidity, parity, education status, age at first intercourse, multiple sexual partners, history of smoking and alcohol use, history of sexually transmitted diseases, history of oral contraceptive and condom use, HPV vaccine history and history of multivitamin use were questioned with a survey.

Results

There was no significant difference between the persistent and non-persistent groups in terms of age, age at first intercourse, age at marriage, gravidity, educational status, oral contraceptive use, smoking and alcohol use, HPV vaccine and multivitamin use. However, there was a significant difference in terms of persistence in patients with multiple sexual partners (p:0.056). In our study, persistence was found to be significantly higher in women who gave birth 2 or more times (p:0.031). In addition, persistence was found to be statistically significantly less in patients who regularly use condoms (p:0.037).

Conclusion

It is important to determine the ways of protection from cervical cancer and its precursor lesions by increasing the patients’ commitment to screening and follow-up, and reducing the factors that may cause persistence with lifestyle changes.

2022-RA-1605-ESGO

PRECISION-PREDICTING RISK OF ENDOMETRIAL CANCER IN ASYMPTOMATIC WOMEN

Sarah Joanne Kitson, Emma Crobie, D Gareth Evans, Antitaya Lophatananon, Kenneth Muir, Daren Ashcroft, Evangelos Kontopantelis, Glen Martin. Division of Cancer Sciences, University of Manchester, Mobberley, UK; Division of Cancer Sciences, University of Manchester, Manchester, UK; Division of Evolution and Genomic Sciences, University of Manchester, Manchester, UK; Institute of Population Health, University of Manchester, Manchester, UK; Division of Pharmacy and Optometry, University of Manchester, Manchester, UK; Division of Informatics, Imaging and Data Science, University of Manchester, Manchester, UK

Introduction/Background

Global endometrial cancer (EC) cases continue to increase, placing a significant health and financial burden on individuals and healthcare services. Effective primary disease prevention strategies are urgently required but remain under-researched. Identifying high-risk women for intervention would ensure therapies are targeted at those most likely to benefit. This study aimed to develop a well-calibrated EC risk prediction model based on routinely collected data and to validate it in an independent cohort.

Methodology

Data from the UK Biobank, comprising 222,031 females ages 45–60 years and 902 incident EC cases, were used to build a flexible parametric survival model using EC risk factors identified through a systematic review of the literature. Model fit was improved with variable transformation and stepwise backward selection. Missing data were dealt with using multiple imputation and bootstrapping (100-fold) was applied for internal validation. Model calibration was assessed using flexible calibration plots and discrimination through calculation of the C-statistic. The model is being externally validated in the Clinical Practice Research Datalink, using data from 3,094,371 women, of whom 20,882 have developed EC.

Results

Age, body mass index, waist circumference, age at menarche, age at last birth, late menopause (≥55 years), current hormone replacement therapy or tamoxifen use, prolonged oral contraceptive pill use (≥5 years), type 2 diabetes, smoking and family history of bowel cancer were incorporated into the model. Based on these variables, the model had an adjusted C-statistic of 0.75 and was well calibrated, with a calibration slope of 0.97 after internal validation.

Conclusion

Our model, using easily measurable anthropometric, lifestyle and reproductive variables alongside personal and family medical history, accurately identifies women at high-risk of EC. External validation will determine whether it can be